Martin Šimkovič

15PUBLICATIONS
90CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Central and Eastern European languages (incl. Russian)Predictive and prognostic markersCellular immunologyComputational linguistics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 12, 2026
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

|Oct 24, 2025
Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel

|Aug 19, 2025
Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Constantine S Tam, Mary Ann Anderson, Martin Šimkovič

|Feb 20, 2025
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

Jennifer R Brown, John F Seymour, Wojciech Jurczak

|Dec 08, 2024
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.

Mazyar Shadman, Talha Munir, Tadeusz Robak

|Sep 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.

Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna

Pageof 3

Frequent Collaborators

6 joint publications

Jennifer R Brown

5 joint publications

Lukáš Smolej

4 joint publications

Pavel Vodárek

4 joint publications

Tadeusz Robak